Published in Lancet on March 15, 2003
Strengthening the role of genomics in global health. PLoS Med (2004) 0.91
Genetics and public health--evolution, or revolution? J Epidemiol Community Health (2004) 0.88
Access and use of human tissues from the developing world: ethical challenges and a way forward using a tissue trust. BMC Med Ethics (2011) 0.88
Pharmacogenomic technologies: a necessary "luxury" for better global public health? Global Health (2011) 0.78
Interpretations of education about gene-environment influences on health in rural Ethiopia: the context of a neglected tropical disease. Int Health (2016) 0.78
The Governance of Genomic Information: Will it Come of Age? Genomics Soc Policy (2006) 0.75
Grand challenges in global mental health. Nature (2011) 8.40
Top ten biotechnologies for improving health in developing countries. Nat Genet (2002) 8.12
Grand challenges in chronic non-communicable diseases. Nature (2007) 7.86
Grand challenges in global health: community engagement in research in developing countries. PLoS Med (2007) 4.75
Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol (2004) 4.30
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: the human proteome. J Proteome Res (2005) 4.13
Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract (2012) 4.11
Advances in proteomics data analysis and display using an accurate mass and time tag approach. Mass Spectrom Rev (2006) 3.80
Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics (2002) 3.57
CPR for patients labeled DNR: the role of the limited aggressive therapy order. Ann Intern Med (2003) 3.54
DAnTE: a statistical tool for quantitative analysis of -omics data. Bioinformatics (2008) 3.51
Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet (2011) 3.23
How much will Herceptin really cost? BMJ (2006) 3.23
Chemically etched open tubular and monolithic emitters for nanoelectrospray ionization mass spectrometry. Anal Chem (2006) 3.22
VIPER: an advanced software package to support high-throughput LC-MS peptide identification. Bioinformatics (2007) 3.15
Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci U S A (2002) 3.15
Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res (2006) 3.10
High-sensitivity ion mobility spectrometry/mass spectrometry using electrodynamic ion funnel interfaces. Anal Chem (2005) 2.99
Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid (2012) 2.85
Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab (2005) 2.79
An IMS-IMS analogue of MS-MS. Anal Chem (2006) 2.68
Whole proteome analysis of post-translational modifications: applications of mass-spectrometry for proteogenomic annotation. Genome Res (2007) 2.67
Decon2LS: An open-source software package for automated processing and visualization of high resolution mass spectrometry data. BMC Bioinformatics (2009) 2.65
Brazilian health biotech--fostering crosstalk between public and private sectors. Nat Biotechnol (2008) 2.57
India's health biotech sector at a crossroads. Nat Biotechnol (2007) 2.53
Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. Mol Cell Proteomics (2005) 2.50
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog (2010) 2.48
Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics (2011) 2.44
Omic data from evolved E. coli are consistent with computed optimal growth from genome-scale models. Mol Syst Biol (2010) 2.41
Binding MOAD (Mother Of All Databases). Proteins (2005) 2.40
Quality care at the end of life. BMJ (2002) 2.40
Ethics and SARS: lessons from Toronto. BMJ (2003) 2.39
DeconMSn: a software tool for accurate parent ion monoisotopic mass determination for tandem mass spectra. Bioinformatics (2008) 2.38
Fully automated four-column capillary LC-MS system for maximizing throughput in proteomic analyses. Anal Chem (2007) 2.38
Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res (2005) 2.35
Integrative analysis of the mitochondrial proteome in yeast. PLoS Biol (2004) 2.31
Statistical characterization of the charge state and residue dependence of low-energy CID peptide dissociation patterns. Anal Chem (2005) 2.29
High dynamic range characterization of the trauma patient plasma proteome. Mol Cell Proteomics (2006) 2.25
High-resolution field asymmetric waveform ion mobility spectrometry using new planar geometry analyzers. Anal Chem (2006) 2.19
Toward plasma proteome profiling with ion mobility-mass spectrometry. J Proteome Res (2006) 2.18
Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics (2006) 2.14
Transport functions dominate the SAR11 metaproteome at low-nutrient extremes in the Sargasso Sea. ISME J (2008) 2.11
Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics (2006) 2.11
Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics (2008) 2.08
A statistical framework for protein quantitation in bottom-up MS-based proteomics. Bioinformatics (2009) 2.07
Development and evaluation of a micro- and nanoscale proteomic sample preparation method. J Proteome Res (2005) 2.06
Setting priorities in health care organizations: criteria, processes, and parameters of success. BMC Health Serv Res (2004) 2.06
The genome of Cyanothece 51142, a unicellular diazotrophic cyanobacterium important in the marine nitrogen cycle. Proc Natl Acad Sci U S A (2008) 2.05
Ionization and transmission efficiency in an electrospray ionization-mass spectrometry interface. J Am Soc Mass Spectrom (2007) 2.03
Fundamentals of traveling wave ion mobility spectrometry. Anal Chem (2008) 2.02
Grand challenges in global health: the ethical, social and cultural program. PLoS Med (2007) 2.02
Clinical microfluidics for neutrophil genomics and proteomics. Nat Med (2010) 2.02
Priority setting in a hospital critical care unit: qualitative case study. Crit Care Med (2003) 2.01
Use of artificial neural networks for the accurate prediction of peptide liquid chromatography elution times in proteome analyses. Anal Chem (2003) 2.00
Chinese health biotech and the billion-patient market. Nat Biotechnol (2008) 2.00
Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal Chem (2004) 2.00
High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology. Anal Chem (2004) 1.99
Binding MOAD, a high-quality protein-ligand database. Nucleic Acids Res (2007) 1.99
Head-to-head comparison of serum fractionation techniques. J Proteome Res (2007) 1.98
Clustering millions of tandem mass spectra. J Proteome Res (2007) 1.98
Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res (2005) 1.96
Spectral archives: extending spectral libraries to analyze both identified and unidentified spectra. Nat Methods (2011) 1.95
Comparative proteome analyses of human plasma following in vivo lipopolysaccharide administration using multidimensional separations coupled with tandem mass spectrometry. Proteomics (2005) 1.94
High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol Cell Proteomics (2004) 1.94
Global profiling of Shewanella oneidensis MR-1: expression of hypothetical genes and improved functional annotations. Proc Natl Acad Sci U S A (2005) 1.93
Ion mobility spectrometry-mass spectrometry performance using electrodynamic ion funnels and elevated drift gas pressures. J Am Soc Mass Spectrom (2007) 1.93
Characterization of the mouse brain proteome using global proteomic analysis complemented with cysteinyl-peptide enrichment. J Proteome Res (2006) 1.93
Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom Rev (2005) 1.91
Ion funnel trap interface for orthogonal time-of-flight mass spectrometry. Anal Chem (2007) 1.88
High-efficiency nanoscale liquid chromatography coupled on-line with mass spectrometry using nanoelectrospray ionization for proteomics. Anal Chem (2002) 1.88
Automated 20 kpsi RPLC-MS and MS/MS with chromatographic peak capacities of 1000-1500 and capabilities in proteomics and metabolomics. Anal Chem (2005) 1.87
Precautionary behavior in response to perceived threat of pandemic influenza. Emerg Infect Dis (2007) 1.84
Robust algorithm for alignment of liquid chromatography-mass spectrometry analyses in an accurate mass and time tag data analysis pipeline. Anal Chem (2006) 1.83
Priority setting: what constitutes success? A conceptual framework for successful priority setting. BMC Health Serv Res (2009) 1.82
Analysis of the Salmonella typhimurium proteome through environmental response toward infectious conditions. Mol Cell Proteomics (2006) 1.82
Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology (2012) 1.82
Improving mass spectrometer sensitivity using a high-pressure electrodynamic ion funnel interface. J Am Soc Mass Spectrom (2006) 1.80
Proteomic analyses using an accurate mass and time tag strategy. Biotechniques (2004) 1.80
PRISM: a data management system for high-throughput proteomics. Proteomics (2006) 1.80
Does trypsin cut before proline? J Proteome Res (2007) 1.79
Enhanced ion utilization efficiency using an electrodynamic ion funnel trap as an injection mechanism for ion mobility spectrometry. Anal Chem (2008) 1.79
A tough transition. Nature (2007) 1.75
Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc Natl Acad Sci U S A (2012) 1.75
Direct mass spectrometric analysis of intact proteins of the yeast large ribosomal subunit using capillary LC/FTICR. Proc Natl Acad Sci U S A (2002) 1.72
Global health. Stagnant health technologies in Africa. Science (2010) 1.68
Comparative proteogenomics: combining mass spectrometry and comparative genomics to analyze multiple genomes. Genome Res (2008) 1.68
Grand challenges in global health: engaging civil society organizations in biomedical research in developing countries. PLoS Med (2007) 1.68
An automated high performance capillary liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometer for high-throughput proteomics. J Am Soc Mass Spectrom (2004) 1.68
Home-based medication review in older people: is it cost effective? Pharmacoeconomics (2007) 1.67
Ultrasensitive proteomics using high-efficiency on-line micro-SPE-nanoLC-nanoESI MS and MS/MS. Anal Chem (2004) 1.66
Charge competition and the linear dynamic range of detection in electrospray ionization mass spectrometry. J Am Soc Mass Spectrom (2004) 1.66
Nanotechnology and the developing world. PLoS Med (2005) 1.66